Compare CPB & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | HALO |
|---|---|---|
| Founded | 1869 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.8B |
| IPO Year | 1994 | 2001 |
| Metric | CPB | HALO |
|---|---|---|
| Price | $21.12 | $63.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $27.75 | ★ $78.18 |
| AVG Volume (30 Days) | ★ 8.8M | 1.4M |
| Earning Date | 03-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.42% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | 1.13 | ★ 2.56 |
| Revenue | ★ $10,253,000,000.00 | $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | $0.97 | $12.79 |
| P/E Ratio | ★ $18.61 | $24.75 |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $20.87 | $47.50 |
| 52 Week High | $40.59 | $82.22 |
| Indicator | CPB | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 21.81 | 31.02 |
| Support Level | N/A | $61.23 |
| Resistance Level | $33.65 | $65.40 |
| Average True Range (ATR) | 0.67 | 1.74 |
| MACD | -0.35 | -0.35 |
| Stochastic Oscillator | 4.26 | 7.10 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.